Developing the LAL business as one of the pillars of growth
First written in FY2016. 22 of 37 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-08-05.
No other company in this theme has enough history to compare yet.
- 2026-08-05AdvancedEarnings
「Net sales increased 19.7% year on year to ¥3,385 million, as overseas sales of endotoxin-testing reagents and in vitro diagnostic products for glucan testing remained strong.」
Strong overseas sales in the LAL business drove a 19.7% year-on-year increase in first-quarter net sales. - FY2026AdvancedAnnual report
「LAL business revenue was ¥12,152 million, up 2.5% year on year.」
LAL business full-year revenue rose 2.5% from the previous fiscal year, driven by strong sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products. - FY2026-H1First-half revenue declined due to the stronger yenAnnual report
「Although overseas sales of glucan-testing in vitro diagnostic products continued to perform well, revenue was ¥5,779 million, down 1.4% year on year due to the yen being stronger than in the same period of the previous year.」
Although overseas sales of glucan-testing in vitro diagnostic products were strong, LAL business first-half revenue declined 1.4% year on year due to the impact of the stronger yen. - FY2025AdvancedAnnual report
「LAL business revenue was ¥11,860 million, up 15.5% year on year.」
LAL business full-year revenue was ¥11,860 million, up 15.5% from the previous fiscal year. - FY2025-H1AdvancedAnnual report
「Revenue was ¥5,863 million, up 18.0% year on year. Revenue increased year on year due to the positive foreign-exchange effect at overseas subsidiary Associates of Cape Cod, Inc., higher sales of glucan-testing in vitro diagnostic products and the recombinant endotoxin-testing reagent PyroSmart NextGen, and strong domestic sales.」
LAL business revenue rose 18.0% year on year, driven by the positive foreign-exchange effect at the overseas subsidiary, higher sales of glucan-testing in vitro diagnostic products and PyroSmart NextGen, and strong domestic sales. - FY2024-Q3Overseas revenue continues to decline as the infectious-disease windfall subsidesAnnual report
「Revenue was ¥7,657 million, down 6.7% year on year. Although domestic sales were broadly in line with the same period of the previous year, revenue at overseas subsidiary Associates of Cape Cod, Inc. declined as the COVID-19-related windfall subsided.」
While domestic sales were broadly in line with the same period of the previous year, LAL business overseas revenue continued to decline as the infectious-disease windfall subsided. The year-on-year revenue decline was 6.7%. - FY2024-Q2Revenue declined due to the reversal of large-equipment sales and the end of the infectious-disease windfallAnnual report
「Revenue was ¥4,970 million, down 10.7% year on year. Domestic sales declined due to the reversal of large-equipment sales in the same period of the previous year, while revenue at overseas subsidiary Associates of Cape Cod, Inc. declined as the COVID-19-related windfall subsided.」
LAL business first-half revenue declined 10.7% year on year due to the reversal of large-equipment sales in the same period of the previous year and the subsiding of the infectious-disease windfall at the overseas subsidiary. - FY2024-Q1Revenue declined as the COVID-19 windfall subsidedAnnual report
「Domestic sales were broadly in line with the same period of the previous year, while revenue at overseas subsidiary Associates of Cape Cod, Inc. fell to ¥2,488 million, down 11.7% year on year, as the COVID-19-related windfall subsided despite a positive foreign-exchange effect.」
Although the weaker yen had a positive effect, overseas subsidiary revenue declined 11.7% year on year as the windfall from the spread of infectious disease subsided. - FY2023-Q3AdvancedAnnual report
「Revenue was ¥8,209 million, up 22.1% year on year, supported by the positive foreign-exchange effect at overseas subsidiary Associates of Cape Cod, Inc. and solid domestic sales.」
LAL business cumulative revenue for the third quarter was ¥8,209 million, up 22.1% year on year, driven by the positive foreign-exchange effect at the overseas subsidiary and solid domestic sales. - FY2023-Q2AdvancedAnnual report
「Revenue was ¥5,566 million, up 26.7% year on year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased with stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., contract testing service orders rose, and domestic sales remained solid.」
LAL business cumulative revenue for the second quarter rose 26.7% year on year, driven by stronger overseas subsidiary sales activities, higher sales of related products, higher contract testing service orders, and solid domestic sales. - FY2023-Q1AdvancedAnnual report
「Revenue was ¥2,819 million, up 35.7% year on year, supported by solid domestic sales, higher sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products resulting from stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., and higher contract testing service orders.」
LAL business revenue rose 35.7% year on year, driven by solid domestic sales, stronger overseas subsidiary sales activities, and higher contract testing service orders. - FY2022AdvancedAnnual report
「Revenue was ¥9,155 million, up 31.9% from the previous fiscal year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased with stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., contract testing service orders rose, and domestic sales remained solid.」
LAL business full-year revenue was ¥9,155 million, up 31.9% from the previous fiscal year, driven by stronger overseas subsidiary sales activities, higher contract testing service orders, and solid domestic sales. - FY2022-Q3AdvancedAnnual report
「Revenue was ¥6,725 million, up 35.6% year on year, supported by solid domestic sales, higher sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products resulting from stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., and higher contract testing service orders.」
LAL business cumulative revenue for the third quarter was ¥6,725 million, up 35.6% year on year, driven by solid domestic sales, stronger overseas subsidiary sales activities, and higher contract testing service orders. - FY2022-Q2AdvancedAnnual report
「Revenue was ¥4,394 million, up 33.2% year on year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased with stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., contract testing service orders rose, and domestic sales remained solid.」
LAL business cumulative revenue rose 33.2% year on year, driven by stronger overseas subsidiary sales activities, higher contract testing service orders, and solid domestic sales. - FY2022-Q1AdvancedAnnual report
「Revenue was ¥2,076 million, up 12.6% year on year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased with stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., contract testing orders increased, and domestic sales remained solid.」
LAL business revenue rose 12.6% year on year, driven by stronger overseas subsidiary sales activities, higher contract testing orders, and solid domestic sales. - FY2021AdvancedAnnual report
「LAL business revenue was ¥6,941 million, up 7.2% year on year.」
LAL business full-year revenue rose 7.2% year on year, supported by stronger sales activities at the overseas subsidiary and solid domestic sales. - FY2021-Q3AdvancedAnnual report
「Revenue was ¥4,960 million, up 1.4% year on year, as both revenue at overseas subsidiary Associates of Cape Cod, Inc. and domestic sales edged up.」
LAL business cumulative revenue rose 1.4% year on year, as revenue at the overseas subsidiary and domestic sales both edged up from levels broadly in line with the same period of the previous year in the preceding quarter. - FY2021-Q2Slight decline due to lower domestic salesAnnual report
「Revenue at overseas subsidiary Associates of Cape Cod, Inc. was broadly in line with the same period of the previous year, as higher sales of glucan-testing in vitro diagnostic products offset lower sales of endotoxin-testing reagents. However, domestic sales declined, resulting in revenue of ¥3,299 million, down 0.6% year on year.」
LAL business revenue declined 0.6% year on year, as growth in glucan-testing in vitro diagnostic products at the overseas subsidiary was outweighed by lower sales of endotoxin reagents and lower domestic sales. - FY2021-Q1AdvancedAnnual report
「Sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased on stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., bringing revenue to ¥1,844 million, up 7.7% year on year.」
LAL business sales of related products increased on stronger overseas subsidiary sales activities, lifting quarterly revenue 7.7% year on year. - FY2020Full-year revenue edged downAnnual report
「Although sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products increased as a result of stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc., domestic sales declined, bringing revenue to ¥6,476 million, broadly in line with the previous fiscal year, down 0.2%.」
LAL business full-year revenue declined 0.2% year on year, as higher product sales resulting from stronger overseas subsidiary sales activities were offset by lower domestic sales. - FY2020-Q3RestatedAnnual report
「Higher sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products resulting from stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc. offset the decline in domestic sales, bringing revenue to ¥4,892 million, broadly in line with the same period of the previous year, up 0.4%.」
LAL business revenue was broadly in line with the same period of the previous year, as higher product sales resulting from stronger overseas subsidiary sales activities offset lower domestic sales. - FY2020-Q2Overall revenue was flat despite higher overseas salesAnnual report
「Although domestic sales declined, higher sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products resulting from stronger sales activities at overseas subsidiary Associates of Cape Cod, Inc. brought revenue to ¥3,319 million, broadly in line with the same period of the previous year, up 0.1%.」
LAL business revenue was broadly in line with the same period of the previous year, as higher sales of related products resulting from stronger overseas subsidiary sales activities offset lower domestic sales. - FY2020-Q1AdvancedAnnual report
「Revenue was ¥1,712 million, up 2.8% year on year, as sales of endotoxin-testing reagents and glucan-testing in vitro diagnostic products performed well, supported by stronger direct sales and distributor activities at overseas subsidiary Associates of Cape Cod, Inc.」
LAL business sales of endotoxin-testing reagents and other products performed well against a backdrop of stronger direct and distributor sales activities, with quarterly revenue up 2.8% year on year. - FY2019AdvancedAnnual report
「LAL business revenue was ¥6,491 million, up 9.4% year on year.」
LAL business revenue for the full year rose 9.4% year on year to ¥6,491 million, with both domestic and overseas sales increasing. - FY2019-Q3AdvancedAnnual report
「Both domestic and overseas sales of endotoxin-testing reagents and related products remained strong, resulting in sales of ¥4.873 billion, up 14.8% year on year.」
LAL business cumulative sales increased 14.8% year on year, with both domestic and overseas sales remaining strong. - FY2019-Q2AdvancedAnnual report
「Both domestic and overseas sales of endotoxin-testing reagents and related products remained strong, resulting in sales of ¥3.317 billion, up 13.0% year on year.」
LAL business sales increased 13.0% year on year, with both domestic and overseas sales remaining strong. - FY2019-Q1AdvancedAnnual report
「Both domestic and overseas sales of endotoxin-testing reagents and related products increased, resulting in sales of ¥1.666 billion, up 15.3% year on year.」
LAL business sales increased 15.3% year on year, with both domestic and overseas sales rising. - FY2018-Q3Cumulative sales growth continuesAnnual report
「Although domestic sales to dialysis hospitals declined, overseas sales of endotoxin-testing reagents and related products, led by the U.S. subsidiary, remained solid. Sales rose 3.3% year on year to ¥4.243 billion.」
LAL business sales increased 3.3% year on year, supported by solid overseas sales despite lower domestic sales to dialysis hospitals. - FY2018-Q2First-half sales growthAnnual report
「Although domestic sales to dialysis hospitals declined, overseas sales of endotoxin-testing reagents and related products, led by the U.S. subsidiary, remained solid. Sales rose 4.7% year on year to ¥2.936 billion.」
LAL business sales increased 4.7% year on year, as solid overseas sales, led by the U.S. subsidiary, offset lower domestic sales to dialysis hospitals. - FY2018-Q1Revenue DeclineAnnual report
「Although overseas sales of endotoxin-testing reagents and related products increased, domestic sales to dialysis hospitals declined, resulting in sales of ¥1.445 billion, down 4.0% year on year.」
LAL business sales declined 4.0% year on year due to lower domestic sales to dialysis hospitals, despite higher overseas sales. - FY2017Continued slight decline in salesAnnual report
「Overseas sales of endotoxin-testing reagents and related products increased in local-currency terms, but were affected by foreign exchange rates. Sales in yen declined 0.1% year on year to ¥5.437 billion.」
Although LAL business sales increased in local-currency terms, sales in yen declined 0.1% year on year due to the impact of foreign exchange rates. - FY2017-Q3Revenue DeclineAnnual report
「Although sales of endotoxin-testing reagents and related products increased, mainly overseas, sales were affected by the stronger yen and declined 0.5% year on year to ¥4.108 billion.」
LAL business sales declined 0.5% year on year due to the impact of the stronger yen, despite higher sales of reagents and related products, mainly overseas. - FY2017-Q2AdvancedAnnual report
「Although overseas sales were affected by the stronger yen, sales increased due to higher domestic and overseas sales of endotoxin-testing reagents and related products, reaching ¥2.803 billion, up 1.8% year on year.」
Despite the impact of the stronger yen, LAL business sales increased 1.8% year on year due to higher domestic and overseas sales of endotoxin-testing reagents and related products. - FY2017-Q1AdvancedAnnual report
「Sales increased primarily due to higher sales of overseas endotoxin-testing reagents and related products, reaching ¥1.505 billion, up 4.1% year on year.」
LAL business sales increased 4.1% year on year, extending its track record as one of the company's growth pillars. - FY2016First statedAnnual report
「The LAL business has grown into one of the pillars supporting the company, driven by increased sales at its U.S. subsidiary.」
LAL business sales increased 11.7% year on year to ¥5.444 billion, establishing the business as one of the company's pillars.